Alert

Compatibility Warning

The main WCB-Alberta website and its online applications use JavaScript technology and some cookies. Please ensure you have JavaScript and cookies enabled in your browser. Visit the help page for more information.

Click here to see an important notice
Workers Compensation Board Alberta Logo

-A A +A

WCB Procedures

  • Help
    • Searching for a procedure or within a procedure
  • 1 - Claim entitlement decisions
    • 1-1 Initial entitlement decision
    • 1-2 Initial entitlement decision - psychiatric or psychological injury
    • 1-3 Initial entitlement decision - hearing loss
    • 1-4 Initial entitlement decision - occupational illness and disease
    • 1-5 Claim reopen (continuation or recurrence) decision
    • 1-6 Aggravation of a pre-existing condition decision
    • 1-7 Reconsider a previous decision (new evidence)
    • 1-8 Fitness-for-work decision
    • 1-9 Conflict of medical/psychologist opinion
    • 1-10 Additional entitlement decision
    • 1-11 Benefits during a medical investigation
    • 1-14 Permanent clinical impairment
    • 1-15 Permanent total disability decision
    • 1-16 Medical assistance in dying
  • 2 - Compensation rate setting and disbursements (payments)
    • 2-1 Rate setting
    • 2-3 Advances and lump sum commutation requests
    • 2-6 Date-of-accident compensation
  • 3 - Return-to-work and care planning
    • 3-1 Modified work
    • 3-2 Collaborative care planning
    • 3-3 Duty to cooperate
    • 3-4 Egregious conduct
    • 3-5 Obligation to reinstate employment
    • 3-8 Medical panel
    • 3-9 Employer-requested medical examination
  • 4 - Medical benefits and services
    • 4-1 Medical testing, referrals and program support
    • 4-2 Community treatments
    • 4-3 Psychological counselling
    • 4-4 Orthotics and prosthetics
    • 4-5 Home health care
    • 4-6 Special services and equipment
    • 4-7 Opioid management
    • 4-8 Pharmacy direct billing and medication management
    • 4-9 Pharmaceutical cannabinoids and medical cannabis
    • 4-10 Externally-powered prosthetics
    • 4-11 Non-standard medical aid treatment decision
    • 4-12 Ketamine or esketamine treatment decision
  • 5 - Claim-related expenses
    • 5-1 Travel and subsistence benefits
    • 5-2 Short-term home assistance
    • 5-3 Housekeeping allowance
    • 5-4 Home maintenance allowance
    • 5-5 Personal care allowance
    • 5-6 Home and workplace modifications
    • 5-7 Vehicle modifications
    • 5-8 Initial hospitalization, treatment center and care facility benefits
    • 5-9 Child and animal care
    • 5-10 Special financial assistance
    • 5-13 Lump sum retirement (pre-retirement) benefit approval
  • 6 - Fatalities
    • 6-1 Initial entitlement decision - fatality claims
    • 6-3 Survivor pension benefit entitlement before September 1, 2018
  • 7 - Re-employment benefits and services
    • 7-1 Triage assessment referral
    • 7-2 Supported job search
    • 7-3 Job option evaluation - suitability, accessibility and salary
    • 7-4 Retraining programs
    • 7-5 Training on the job, train and place, or work assessment
    • 7-6 Designated public service employers
    • 7-7 Relocation assistance
    • 7-8 Alternate grants -retraining and self-employment
    • 7-9 Tools and equipment
  • 8 - Wage loss supplements
    • 8-1 Wage-loss supplement (WLS) final approval
    • 8-2 Retroactive wage loss supplement final approval
    • 8-3 Temporary partial disability benefit (TPD) reviews
    • 8-4 Temporary economic loss (TEL) benefit reviews
    • 8-5 Economic loss payment (ELP) reviews
    • 8-6 Earnings loss supplement (ELS) reviews
  • 9 - Claim information, access and privacy
    • 9-1 Collection and correction of claim information
    • 9-4 Authorizations: worker and employer representatives
  • 10 - Client inquiries and incidents
    • 10-1 Client inquiry resolution
    • 10-2 Respectful communication
    • 10-3 Critical incidents
    • 10-4 Address a fairness inquiry
  • 11 - Claim and file administration
    • 11-1 Requesting medical reports
    • 11-2 Internal consultant referrals
    • 11-4 Translation and interpretation services
    • 11-5 Claim entitlement Investigation Unit referrals
    • 11-8 Guardianship and trusteeship
  • 12 - Cost and entitlement adjustments
    • 12-1 Cost relief, cost transfer and cost reallocation
    • 12-3 Overpayments, cost corrections and payments on hold
  • 13 - Claim decision review and appeal
    • 13-1 Address a resolution submission or letter
    • 13-2 Request for review (RFR)
    • 13-3 DRDRB decision implementation

Ketamine or esketamine treatment decision

Procedure summary

Published On

Oct 20, 2026
Purpose

To determine authorization for ketamine or esketamine treatment for injured workers.

Description

The decision maker reviews each applicationApplication form C1520 is required for consideration of IV ketamine, esketamine or treatment resistant depression. for ketamine/esketamine treatmentIV ketamine, esketamine , submitted by the treating specialist (i.e., psychiatrist, neurologist, physiatrist or anesthesiologist).

The decision maker works collaboratively with the worker, treating specialistA specialist physician, such as a neurologist, psychiatrist, physiatrist, or anesthesiologist who is treating the worker for the condition that ketamine is requested for.(s) and medical provider(s) to compile the necessary information to develop the worker's treatment plan. They offer education and provide alternatives for pain management such as psychological counselling, other medications, or multidisciplinary programs.

If the worker is eligible for consideration for ketamine/esketamine treatment, the decision maker refers all requests to the internal medical consultant to determine if ketamine/esketamine can be medically supported based on the criteria outlined in Policy 04-06, Part II, Application 1. 

The decision maker assesses all the available evidence and submits their request to the supervisor for approval. The supervisor documents their decision to approve or not approve the recommendations and forwards it to the next approver level, if required. 

The decision maker notifies the injured worker and treating specialist of the decision to approve or not approve the ketamine/esketamine treatment.

Key information

Ketamine is a hallucinogenic drug that is used primarily for anesthesia. It has also been explored for off-label uses, such as psychiatric conditions. It is a controlled substance under Schedule 1 with a high potential for harm and abuse. Only requests for IV ketamine for an initial trial will be considered.  

Esketamine is an intranasal formulation of ketamine, licensed in Canada for the treatment of moderate to severe major depressive disorder where patients have not responded to other antidepressants, or where urgent psychiatric care is required. Only requests for SPRAVATO® as intranasal esketamine for the treatment of treatment-resistant depression (TRD) will be considered. 

Requests for ketamine/esketamine, may be considered based on the application form submitted by the treating specialistA specialist physician, such as a neurologist, psychiatrist, physiatrist, or anesthesiologist who is treating the worker for the condition that ketamine is requested for.(s). Pre-approval is required; therefore, no treatment can be approved while the request is under review. These requests must be reviewed by Medical Services. Following this review, a Psychiatric Expedited Specialist ConsultationThis exam assesses a worker's treatment recommendations and is initiated by the medical consultant when considering ketamine/ esketamine treatment. It is performed in person by a psychiatric specialist also capable of performing independent medical examinations. may be recommended. For treatment requests for non-psychiatric conditions, an Independent Medical Examination may be recommended as well. A medical consultant then reviews the results of the Psychiatric Expedited Specialist Consultation or Independent Medical Examination.

When determining eligibility for ketamine/esketamine treatment, the following criteria must be met:

  • The treatment is for psychiatric conditionsDSM-5 treatment resistant depression, major depressive disorder, and some chronic pain conditions. and/or chronic pain conditions resulting from a compensable injury.
  • Requested ketamine/esketamine must be the sole new therapy (not with other treatments such as rTMSTranscranial magnetic stimulation (TMS) is a procedure that uses magnetic fields to stimulate nerve cells in the brain to improve symptoms of major depression. It's called a "noninvasive" procedure because it's done without using surgery or cutting the skin. During an rTMS session for depression, an electromagnetic coil is placed against the scalp of the head. This coil delivers magnetic pulses that stimulate nerve cells in the region of the brain involved in mood control and depression. to ensure that response can be determined. As ketamine/esketamine is considered adjunctive therapy for major depressive disorder, it will be added to other antidepressants).
  • It can be legally provided in Canada from an accredited source.

The worker is not eligible for consideration of ketamine/esketamine treatment in the following circumstances: 

  • Under the age of 18 years
  • History of primary psychotic disorder
  • Inability to provide informed consent
  • Pregnancy or breastfeeding
  • Allergy to ketamine.

WCB Alberta requires compliance with all current regulatory requirements for the safe administration of ketamine/esketamine, with or without psychedelic-assisted psychotherapy. 

Following this review, the decision maker may decide to approve an initial trial of ketamine/esketamine treatment. If approved, the decision maker refers for the appropriate treatment with an authorized contracted provider. To maintain neutrality, WCB separates the role of assessment for the appropriateness of complicated therapies from the administration and delivery of these therapies. Further approval after the initial trial is dependent on documented benefit as determined by WCB Alberta and beneficial effect on recovery and progress to return to work (RTW).

Detailed business procedure

Expand all

Collapse all

1. Review the request for ketamine/esketamine treatment

Review the claim and determine if the worker may be eligible for ketamine/esketamine treatment as outlined in the key information section. If the worker is not eligible for consideration of ketamine treatment, continue to step 6 to communicate the decision. 

Note: If ketamine/esketamine was approved without meeting the applicable requirements (e.g., application form, medical consultant opinion, psychiatric expedited specialist consultation, etc.), the treatment provider must submit a ketamine - esketamine medication report for review. Once the report is received, continue to step 2.

If the worker may be eligible for ketamine/esketamine treatment IV ketamine, esketamine, review the applicationApplication for trial of ketamine (C1520) is required for consideration of IV ketamine, esketamine, or treatment resistant depression. from the treating specialistA specialist physician, such as a neurologist, psychiatrist, physiatrist, or anesthesiologist who is treating the worker for the condition that ketamine is requested for.(s). Confirm the required documentation is completed and received. 

Reach out to a medical or clinical consultant if you need clarification on the request (e.g., whether the request came from a treating specialist, what diagnosis is being treated, or if the documentation is appropriate, etc.).

If any information is missing or incomplete, contact the worker and treating specialist to discuss the requirements to consider ketamine/esketamine treatment. Explain that an application form outlining the proposed treatment plan is required from the treating specialist.  Explore other standard treatment options that are commonly used and widely accepted that the worker has not tried, as appropriate.  If all standard treatment options have been exhausted, send the Request for Ketamine Treatment Information letter educating them on the requirements for ketamine/esketamine to be considered.

Once all the required documentation is received, continue to the next step.

If the request was received from anyone other than a treating specialist (i.e., psychiatrist, neurologist, physiatrist or anesthesiologist) contact the requestor and send the Request for Ketamine Treatment Information letter outlining the requirements for consideration of ketamine/esketamine treatment. If the request follows a psychiatric independent medical exam, send the letter to the general practitioner instead. 

Administrative tasks

Document the discussion in a file note (Contact/Worker).

 

Refer to the Resource Library for additional information.

 

 

 

Send the Request for Ketamine Treatment Information (SP038A) letter requesting any outstanding information. This letter includes the following documents:

  • Application for Trial of Ketamine - Esketamine (C1520)
  • Ketamine - Esketamine Medication Report (C1521)
  • Worker Fact Sheet - Ketamine Treatment WFS Ketamine treatment.pdf
  • Health Care Provider Fact Sheet - Ketamine/ esketamine Requests HCP Ketamine requests.pdf 
2. Make the referral to an internal medical consultant

Prior to making the initial referral to the internal medical consultant, ensure: 

  • the injuries and/or conditions accepted and not accepted on the claim are up to date.
  • the application form is fully completed.

For subsequent medical consultant referrals (i.e., prior approvals, further actions completed, extension requests, treatment concerns, discharge recommendations, etc.) reference the applicable medical reporting and reason for the referral. 

Once all the information is available for review, make the referral to the internal medical consultant. 

The medical consultant reviews the request for the ketamine/esketamine treatment and provides a medical opinion on whether there is current evidence to support ketamine/esketamine treatment. In some cases, the consultant may recommend alternative treatments or a Psychiatric Expedited Specialist Consultation. If a Psychiatric Expedited Specialist Consultation is recommended, the specialist will evaluate any contraindications during the assessment. 

Administrative tasks

Ensure all the eCO screens are up to date including the injury details, treatment details.

 

Send the MC Review (FM555C) form. Request a ketamine/esketamine medication review and include additional questions as appropriate.

Follow the 11-2 Internal consultant referrals procedure. 

3. Review the medical opinion and action their recommendations, if needed

Review the medical consultant's opinion. Reach out to the medical consultant when clarification of their opinion is required. When the medical opinion: 

  • recommends further action, (i.e., clarify entitlement, alternative treatment options, independent medical exam (IME), etc.) contact the worker to discuss the recommendations and the next steps. If applicable, send the appropriate referral. Once the recommended action is completed and the reporting is received, return to step 2.
  • recommends a Psychiatric Expedited Specialist Consultation, contact the worker and treating specialist to discuss the recommendation. Send the appropriate referral. Include in the referral, a request for a proposed treatment plan if the treating specialist did not provide one (i.e., the worker was referred to a ketamine clinic). Continue to the next step.
  • does not support the proposed treatment, continue to step 6 to communicate the decision. 

Administrative tasks

Follow 4-1 Medical testing, referrals and program support  to complete any recommended referrals.

4. Review the Psychiatric Expedited Specialist Consultation

Review the Psychiatric Expedited Specialist Consultation (ESC) report 

When the specialist’s report: 

  • does not support the proposed treatment, continue to step 6 to communicate the decision.
  • supports the proposed treatment as recommended, or with modifications or additional assessments If the compensable condition is a non-psychiatric condition, an additional assessment may be required. This would be outlined in the ESC report., send a referral to the medical consultant who recommended the psychiatric expedited specialist consultation. The medical consultant may contact the specialist to discuss the treatment plan to ensure it remains medically reasonable. 
Review the medical consultant's opinion

When the medical opinion:

  • supports the treatment plan, continue to the next step.
  • does not support the treatment plan, continue to step 6 to communicate the decision.  

Administrative tasks

If applicable, document the discussion in a file note (Medical Aid).

Send the MC Review (FM555C) form. Request a ketamine/esketamine medication review and reference the Psychiatric Expedited Specialist Consultation report.

Follow the 11-2 Internal consultant referrals procedure. 

 

5. Request approval for the proposed treatment

Send a recommendation to the supervisor to confirm the proposed treatment is appropriate. Include the following information: 

  • The injuries and/or conditions accepted and not accepted on the claim.
  • A brief summary of the proposed treatment and a reference to any information on file submitted by the treating specialist and/or psychiatric expedited specialist consultation.
  • Reference to the medical consultant's opinion on file.
  • How the proposed treatment meets all the criteria outlined in Policy 04-06, Part II, Application 1.

The supervisor documents their decision to approve or not approve the recommendations and forwards it to the next approver level, if required. Refer to the Levels of Authority manual.

Review the response

Review the supervisor's (and manager, if applicable) recommendation to approve or not approve ketamine/esketamine treatment. 

If additional information is needed, action the supervisor’s (and manager, if applicable) recommendations and resubmit the recommendation.

Administrative tasks

Send a file note (Medical Aid) with the description line, Request for approval for ketamine treatment, to the supervisor.

Refer to the Levels of Authority Manual. 

6. Make and communicate the decision

Review the supervisor's response to approve or not approve the ketamine/esketamine treatment. Action any recommendations, as appropriate. 

Contact the worker to discuss the decision and explain the information used to support the decision. 

If approved: 

  • Advise the worker that treatment is arranged and administered through a contracted provider whenever possible. Explain the provider will contact them to arrange the initial intake assessment.
  • Discuss the length of the initial trial approval and the expectations during treatment.
  • Communicate the decision in writing to the worker and send a copy to the treating specialist. Include the specific details about the proposed treatment or services authorized and when the treatment will be reviewed.
  • Continue to the next step to make the referral.
  • If the worker is engaged in WCB-supported counselling, send a referral to a psychological consultant to comment on the counselling treatment plan. This should not delay the approval process of the ketamine/esketamine treatment plan. 

If not approved, or the worker is not eligible for ketamine/esketamine treatment: 

  • Discuss any alternative standard medical treatment, if recommended by the medical consultant. 
  • Communicate the decision in writing to the worker and send a copy to the requestor or treating specialist. 
If a subsequentA subsequent request may include, changes in the treatment plan, extension requests, prior approvals, concerns with the worker's progress, discharge requests. request was reviewed and the worker:
  • meets the criteria for an extension or change in treatment plan, explain that authorization will be provided based on the medical consultant's recommendations with reviews every three months, or earlier, to ensure the worker continues to meet the criteria for approval. Document the discussion and communicate the decision in writing. Continue to Step 8. 
  • does not meet the criteria for ongoing treatment or has been discharged. Explain why they no longer meet all of the criteria. Document the discussion and communicate the decision in writing.
    • Discontinue ketamine/esketamine treatment and do not continue further with this procedure.
    • Continue to manage the claim and consider alternative treatment options.

Administrative tasks

Document the discussion in a file note (Contact/Worker).

Document decision for the ketamine/esketamine treatment in a file note (Medical Pmt Processing). Include the duration for the authorization (i.e., start and end dates for approval).

Update the Benefits Details screen on the Authorized Medication line (AUM).

Follow the 11-2 Internal consultant referrals procedure. 

Send the appropriate letter:

  • Ketamine Treatment - Approval (CL038A)
  • Ketamine Treatment - Denial (CL038C)
  • Ketamine Treatment - Extension (CL038B)

If applicable, from the eCO Create Referral screen, send the psychological consultant referral (Psych – IED, Tx, Cost Relief–FM555M) form.

 

7. Make the referral, if appropriate.

Complete the referral form with the reason for the referral, proposed treatment plan, and any concerns noted in the psychiatric ESC report or the medical consultant's review. 

Once the contracted provider (administering clinic) has been confirmed by the Psychology Assistant (PA), the administering clinic arranges the initial intake assessment with the worker. 

Following the intake assessment, the administering clinic arranges a case conference with the claim owner to review the assessment findings and confirm whether treatment can proceed.

If clinical concerns are identified during the intake assessment or at any point during treatment, the administering clinic arranges a case conference with the claim owner to discuss the concerns and determine the appropriate next steps. Document any concerns and consult the medical consultant who reviewed the initial request, as appropriate (e.g., discontinuing treatment, considering alternative options, etc.).

Note: Any requests to attend a non-contracted or out of province provider require advanced approval from the Health Care Consultant and are discussed with the Supervisor.

Administrative tasks

From the eCO Create Referral screen, select Comprehensive psychological assessment and neuropsychological assessment and complete all sections of the FM008A form to ensure the services can be arranged without delay.

The Psychology Assistant (PA) arranges the referral and sends the following letter to the provider: 

  • Ketamine Treatment - Provider Referral (SP038B)
  • Or, if applicable, Ketamine Treatment - Non-contracted Provider referral (SP038C)

Document the case conference in a file note (contact/treatment provider contact).

Update the eCO travel expense line and request travel benefits, if needed.

Refer to the Resource Library for additional information.

8. Monitor the treatment

During the approval period Typically an initial trial period for other conditions may be approved of up to 3 months. Treatment resistant depression may be approved as in initial trial of six (6) administrations of IV ketamine or four (4) weeks of induction SPRAVATO® as an adjunctive therapy. Refer to the proposed treatment plan provided by the specialist.

Call the worker monthly, or as needed, based on the claim circumstances, to discuss their treatment and progress. Talk to them about how the treatment is going. Communicate the treatment plan in writing. 

If applicable, review the psychological consultant’s memo and determine how it impacts the claim and if further action is recommended (i.e., change in treatment approach or alternate counselling provider). If appropriate, contact the worker to discuss the consultant’s recommendations and the next steps, if any. Reach out to the psychological consultant when clarification of their opinion is required. 

Ensure the treatment is in line with the approved treatment plan related to injury(ies). Reach out to a medical consultant if there are concerns with the treatment plan and progress.  

Monitor for updated medical reporting from the contracted provider and the treating specialist. The treating specialistA specialist physician, such as a neurologist, psychiatrist, physiatrist, or anesthesiologist who is treating the worker for the condition that ketamine is requested for.(s) must provide an updated medication reportKetamine - Esketamine Medication Report (C1521) at minimum every three months, or whenever there are concerns with the treatment plan to ensure the worker continues to meet the criteria for approval. 

Note: If ketamine/esketamine was approved without meeting the applicable requirements (e.g., application form, medical consultant opinion, psychiatric expedited specialist consultation, etc.), a medication report should be completed and submitted for review. Once received, return to step 2 and complete steps 2 through 6.

If an extension of treatment was approved, continue to monitor the claim during the approval period as outlined above. 

At the end of the approval period 

Call the worker and gather their opinion on the treatment results and how they felt about the treatment. 

Review all medical reporting from the contracted provider and the treating specialistA specialist physician, such as a neurologist, psychiatrist, physiatrist, or anesthesiologist who is treating the worker for the condition that ketamine is requested for.(s) and consider the effectiveness of the treatment and any benefits, the worker is experiencing. Note any side effects or changes to the approved treatment plan. 

Once reviewed, return to step 2 and complete steps 2 through 6. The medical consultant reviews all requests for extensions, discharge, treatment plan modifications or clinical concerns.

In all cases, contact the worker and discuss the next steps based on the treating specialist'sA specialist physician, such as a neurologist, psychiatrist, physiatrist, or anesthesiologist who is treating the worker for the condition that ketamine is requested for. medication report and the medical consultants review. 

For claims where psychological counselling is ongoing, ensure the counselling provider is up to date with the ketamine/esketamine decisions and continue to review for an extension. 

Administrative tasks

Document the discussion in a file note (Medical Payment Processing).

Send the Care Plan Update letter (CL041F) outlining the treatment approval dates, duration of treatment and recovery plan goals. 

Update the Benefits Details screen on the Authorized Medication line (AUM).

Follow the 11-2 Internal consultant referrals procedure.

 

 

 

Send the Ketamine - Esketamine Medication Report (C1521), to the treating specialist if required. 

 

 

 

 

 

 

 

 

For psychological counselling extensions, follow 4-3 Psychological counselling.

Supporting references

Policies

  • Policy 04-06, Part I
  • Policy 04-06, Part II, Application 1
  • Policy 04-06, Part II, Application 4

Procedures

  • 4-1 Medical testing, referrals and program support
  • 4-11 Non-standard medical aid treatment decision
  • 11-2 Internal consultant referrals

Workers’ Compensation Act

Applicable Sections

  • Section 1(1) - Interpretation
  • Section 34 - Report by physician
  • Section 38 - Medical exam and investigation
  • Section 56 - Disability
  • Section 80 - Amount of medical aid

Workers' Compensation Regulation

Applicable Sections

Related Legislation


Procedure history

March 2, 2026 - October 19, 2026
WCB logo image

Contact WCB-Alberta

Edmonton: 780-498-3999
Calgary: 403-517-6000

Toll free

Alberta: 1-866-922-9221
Canada wide: 1-800-661-9608

Copyright ©2023 The Workers' Compensation Board – Alberta. All rights reserved.